Emicizumab OverviewEmicizumab (trade name Hemlibra) is a humanized bispecific antibody for the treatment of haemophilia A, developed by Chugai (a subsidiary of Roche). A Phase I clinical trial found that it was well tolerated by healthy subjects. In November 2017, it was approved by the US FDA for treatment of haemophilia A in those who had developed resistance to other treatments. It was subsequently approved by the US FDA in April 2018 under the breakth...
Read more Emicizumab Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Emicizumab
Recent Emicizumab Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 105mg/0.7ml, 150mg, 30mg/ml, 60mg/0.4ml
Other drugs which contain Emicizumab or a similar ingredient: (1 result)
- HEMLIBRA Emicizumab